熱門資訊> 正文

ImmunityBio获得8000万美元融资

2025-07-25 18:10

ImmunityBio Inc Ordinary Shares(IBRX) 0
纳比特(NA) 0
盛大科技(SDA) 0

ImmunityBio (NASDAQ:IBRX) has secured new financing to provide further working capital and support its ongoing business operations.
The company entered into a securities purchase agreement with two institutional investors for a registered direct offering, which includes the sale of common stock and accompanying warrants to purchase additional shares.
The deal is expected to generate around $80 million in gross proceeds at closing.
If the warrants are fully exercised, the company could receive up to an around $96 million in gross proceeds.
IBRX +2.9% premarket to $3.1
Source: Press Release

More on ImmunityBio

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。